(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- 5 Wellbeing Applications Assist You With remaining Fit
- Grasping the Basics of Business Land Regulation
- A definitive Manual for Web based Mastering and Expertise Improvement
- Financial plan Cordial Home Redesigns That Add Worth
- Top 10 Books That Will Have an impact on Your Viewpoint
- The most effective method to Pick the Best Material Organization: Insider Tips
- Sports Shoes of 2024: Upgrade Execution and Solace
